A Comparison of Demographics, Disease Activity, Disability, and Treatment Among Rheumatoid Arthritis Patients with and without Osteoporosis

References

• Abdulkhaliq A. Bones and rheumatology. In: Almoallim H, Cheikh M, editors. Skills in Rheumatology. Singapore: Springer Singapore; 2021:209–239.
   Google Scholar
• Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. doi:10.1038/nrdp.2018.1
   PubMed Web of Science ®Google Scholar
• Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359(9321):1929–1936. doi:10.1016/S0140-6736(02)08761-5
   PubMed Web of Science ®Google Scholar
• Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int. 2021;41(5):863–877. doi:10.1007/s00296-020-04731-0
   PubMed Web of Science ®Google Scholar
• Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum. 2000;43(3):522–530. doi:10.1002/1529-0131(200003)43:3<522::AID-ANR7>3.0.CO;2-Y
   PubMed Web of Science ®Google Scholar
• Hauser B, Riches PL, Wilson JF, Horne AE, Ralston SH. Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis. Rheumatology. 2014;53(10):1759–1766. doi:10.1093/rheumatology/keu162
   PubMed Web of Science ®Google Scholar
• Sinigaglia L, Nervetti A, Mela Q, et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol. 2000;27(11):2582–2589.
   Web of Science ®Google Scholar
• Haugeberg G, Helgetveit KB, Førre Ø, Garen T, Sommerseth H, Prøven A. Generalized bone loss in early rheumatoid arthritis patients followed for ten years in the biologic treatment era. BMC Musculoskelet Disord. 2014;15:289. doi:10.1186/1471-2474-15-289
   Web of Science ®Google Scholar
• Mori Y, Kuwahara Y, Chiba S, et al. Bone mineral density of postmenopausal women with rheumatoid arthritis depends on disease duration regardless of treatment. J Bone Miner Metab. 2017;35(1):52–57. doi:10.1007/s00774-015-0716-9
   Web of Science ®Google Scholar
• Fassio A, Idolazzi L, Jaber MA, et al. The negative bone effects of the disease and of chronic corticosteroid treatment in premenopausal women affected by rheumatoid arthritis. Reumatismo. 2016;68(2):65–71. doi:10.4081/reumatismo.2016.878
   Google Scholar
• Kweon S-M, Sohn DH, Park J-H, et al. Male patients with rheumatoid arthritis have an increased risk of osteoporosis: frequency and risk factors. Medicine. 2018;97(24):e11122–e. doi:10.1097/MD.0000000000011122
   PubMed Web of Science ®Google Scholar
• Orsolini G, Caimmi C, Viapiana O, et al. Titer-dependent effect of anti-citrullinated protein antibodies on systemic bone mass in rheumatoid arthritis patients. Calcif Tissue Int. 2017;101(1):17–23. doi:10.1007/s00223-017-0253-8
   PubMed Web of Science ®Google Scholar
• Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012;11(5):401–419. doi:10.1038/nrd3705
   PubMed Web of Science ®Google Scholar
• Rossini M, Gatti D, Adami S. Involvement of WNT/β-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int. 2013;93(2):121–132. doi:10.1007/s00223-013-9749-z
   PubMed Web of Science ®Google Scholar
• Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev. 2008;29(4):403–440.
   PubMed Web of Science ®Google Scholar
• Schett G, Saag KG, Bijlsma JW. From bone biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis. 2010;69(8):1415–1419. doi:10.1136/ard.2010.135061
   Web of Science ®Google Scholar
• Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13(2):156–163. doi:10.1038/nm1538
   PubMed Web of Science ®Google Scholar
• Ma Y, Zhang X, Wang M, et al. The serum level of Dickkopf-1 in patients with rheumatoid arthritis: a systematic review and meta-analysis. Int Immunopharmacol. 2018;59:227–232. doi:10.1016/j.intimp.2018.04.019
   Web of Science ®Google Scholar
• Terpos E, Fragiadaki K, Konsta M, Bratengeier C, Papatheodorou A, Sfikakis PP. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. Clin Exp Rheumatol. 2011;29(6):921–925.
   PubMed Web of Science ®Google Scholar
• Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73(1):62–68. doi:10.1136/annrheumdis-2013-204223
   PubMed Web of Science ®Google Scholar
• Richards JS, Cannon GW, Hayden CL, et al. Adherence with bisphosphonate therapy in US veterans with rheumatoid arthritis. Arthritis Care Res. 2012;64(12):1864–1870. doi:10.1002/acr.21777
   Web of Science ®Google Scholar
• Orgnization WH. WHO Scientific Group on The Assessment Of Osteoporosis At Primary Health Care LeveL. Summary Meeting Report Brussels, Belgium;2004. Available from: https://www.who.int/chp/topics/Osteoporosis.pdf..
   Google Scholar
• Briot K, Roux C. Glucocorticoid-induced osteoporosis. RMD Open. 2015;1(1):e000014. doi:10.1136/rmdopen-2014-000014
   PubMed Web of Science ®Google Scholar
• Hoes JN, Bultink IE, Lems WF. Management of osteoporosis in rheumatoid arthritis patients. Expert Opin Pharmacother. 2015;16(4):559–571. doi:10.1517/14656566.2015.997709
   PubMed Web of Science ®Google Scholar
• Prevoo ML, van ‘T Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44–48.
   PubMed Web of Science ®Google Scholar
• Almoallim H, Hassan R, Cheikh M, et al. Rheumatoid Arthritis Saudi Database (RASD): disease Characteristics and Remission Rates in a Tertiary Care Center. Open Access Rheumatol. 2020;12:139–145. doi:10.2147/OARRR.S260426
   PubMed Web of Science ®Google Scholar
• Küçükdeveci AA, Sahin H, Ataman S, Griffiths B, Tennant A. Issues in cross-cultural validity: example from the adaptation, reliability, and validity testing of a Turkish version of the Stanford Health Assessment Questionnaire. Arthritis Rheum. 2004;51(1):14–19. doi:10.1002/art.20091
   PubMed Web of Science ®Google Scholar
• Hooyman JR, Melton LJ 3rd, Nelson AM, O’Fallon WM, Riggs BL. Fractures after rheumatoid arthritis. A population-based study. Arthritis Rheum. 1984;27(12):1353–1361.
   PubMed Web of Science ®Google Scholar
• Gough AKS, Emery P, Holder RL, Lilley J, Eyre S. Generalised bone loss in patients with early rheumatoid arthritis. The Lancet. 1994;344(8914):23–27. doi:10.1016/S0140-6736(94)91049-9
   PubMed Web of Science ®Google Scholar
• Laan RF, Buijs WC, Verbeek AL, et al. Bone mineral density in patients with recent onset rheumatoid arthritis: influence of disease activity and functional capacity. Ann Rheum Dis. 1993;52(1):21–26. doi:10.1136/ard.52.1.21
   Web of Science ®Google Scholar
• Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis. 1995;54(1):49–52. doi:10.1136/ard.54.1.49
   Web of Science ®Google Scholar
• Pouresmaeili F, Kamalidehghan B, Kamarehei M, Goh YM. A comprehensive overview on osteoporosis and its risk factors. Ther Clin Risk Manag. 2018;14:2029–2049. doi:10.2147/TCRM.S138000
   PubMed Web of Science ®Google Scholar
• Kleyer A, Finzel S, Rech J, et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis. 2014;73(5):854–860. doi:10.1136/annrheumdis-2012-202958
   PubMed Web of Science ®Google Scholar
• Sadat-Ali M, Al-Habdan IM, Al-Turki HA, Azam MQ. An epidemiological analysis of the incidence of osteoporosis and osteoporosis-related fractures among the Saudi Arabian population. Ann Saudi Med. 2012;32(6):637–641. doi:10.5144/0256-4947.2012.637
   Web of Science ®Google Scholar
• Darawankul B, Chaiamnuay S, Pakchotanon R, Asavatanabodee P, Narongroeknawin P. The good EULAR response at the first year is strongly predictive of clinical remission in rheumatoid arthritis: results from the TARAC cohort. Clin Rheumatol. 2015;34(1):43–49. doi:10.1007/s10067-014-2749-1
   Web of Science ®Google Scholar
• Barnabe C, Homik J, Barr SG, Martin L, Maksymowych WP. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy. J Rheumatol. 2014;41(8):1607–1613. doi:10.3899/jrheum.131451
   Web of Science ®Google Scholar
• Hafez EA, Mansour HE, Hamza SH, Moftah SG, Younes TB, Ismail MA. Bone mineral density changes in patients with recent-onset rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2011;4:87–94. doi:10.4137/CMAMD.S7773
   Google Scholar
• Takeuchi T, Tanaka Y, Ishiguro N, et al. Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, Phase II clinical trial. Ann Rheum Dis. 2016;75(6):983–990.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tanaka Y, Soen S, et al. Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled Phase 3 trial. Ann Rheum Dis. 2019;78(7):899–907.
   PubMed Web of Science ®Google Scholar